Novartis To Pay Daiichi $182M In Deal To End Appeal
Novartis Pharmaceuticals has agreed to pay $182 million to Daiichi Sankyo subsidiary Plexxikon as part of a settlement in a patent infringement case over skin cancer drug Tafinlar after Novartis appealed...To view the full article, register now.
Already a subscriber? Click here to view full article